Title: A novel time-based surface EMG measure for quantifying hypertonia in paretic arm muscles during daily activities after hemiparetic stroke

Authors: M. Hongchul Sohn[1,*], Jasjit Deol[1,2] and Julius P.A. Dewald[1,3,4]

[1] Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine Northwestern University, Chicago IL, USA

[2] Neuroscience and Mental Health Institute Graduate Program, University of Alberta, Edmonton AB, Canada

[3] Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston IL, USA

[4] Department of Physical Medicine and Rehabilitation, Feinberg School of Medicine, Northwestern University, Evanston IL, USA

[*] Correspondence: hongchul.sohn@northwestern.edu

Keywords: EMG; Stroke; Arm Motor Deficit; Remote Monitoring; Home-based Setting

ABSTRACT

After stroke, paretic arm muscles are constantly exposed to abnormal neural drive from the injured brain. As such, hypertonia, broadly defined as an increase in muscle tone, is prevalent especially in distal muscles, which impairs daily function or in long-term leads to a flexed resting posture in the wrist and fingers. However, there currently is no quantitative measure that can reliably track how hypertonia is expressed on daily basis. In this study, we propose a novel time-based surface electromyography (sEMG) measure that can overcome the limitations of the coarse clinical scales often measured in functionally irrelevant context and the magnitude-based sEMG measures that suffer from signal non-stationarity. We postulated that the key to robust quantification of hypertonia is to capture the "true" baseline in sEMG for each measurement session, by which we can define the relative duration of activity over a short time segment continuously tracked in a sliding window fashion. We validate that the proposed measure of sEMG active duration is robust across parameter choices (e.g., sampling rate, window length, threshold criteria), robust against typical noise sources present in paretic muscles (e.g., low signal-to-noise ratio, sporadic motor unit action potentials), and reliable across measurements (e.g., sensors, trials, and days), while providing a continuum of scale over the full magnitude range for each session. Furthermore, sEMG active duration could well characterize the clinically observed differences in hypertonia expressed across different muscles and impairment levels. The proposed measure can be used for continuous and quantitative monitoring of hypertonia during activities of daily living while at home, which will allow for the study of the practical effect of pharmacological and/or physical interventions that try to combat its presence.

1. INTRODUCTION

Upper extremity motor impairment after stroke is a major contributor to loss of function in daily life. Among many neurological conditions that impair control of the paretic arm, hypertonia, broadly defined as an increase in muscle tone, commonly appears in individuals with hemiplegic stroke [1, 2]. Hypertonia is clinically observed to be most prevalent in distal flexor muscles [1, 3, 4]. Cumulating evidence suggests that hypertonia present in wrist and finger muscles may be linked to the upregulation of the corticoreticulospinal system following a loss of corticobulbar projections from the lesioned hemisphere [5]. As a result, individuals with severe motor impairment after stroke often have difficulties in using their hand, for example, opening the hand or extending the wrist, which is detrimental to many activities of daily living [6]. Studies suggest that prolonged exposure to such abnormal neural drive may further impact musculoskeletal changes in the paretic arm, leading to a flexed resting posture or contractures [7, 8]. Consequently, current treatment of hypertonia largely focuses on wrist/finger and sometimes elbow flexor muscles, which include focal injection of botulinum toxin [9-11], use of wrist/finger orthosis or splints [9, 12, 13], electrical stimulation [14], stretching [15, 16], and surgical procedures such as tendon transfers [17-19].

However, there currently is no quantitative measure that can be used to constantly track how hypertonia is expressed in wrist and fingers muscles, which is crucial for understanding the true impact of hypertonia in daily function or objectively assessing the effectiveness of afore-mentioned treatments, e.g., pre and post intervention. Hypertonia in clinic is currently assessed using coarse scores such as the Modified Ashworth Scale (MAS) [20-22] and the Modified Tardieu Scale [23]. On the other hand, many studies have also attempted to assess hypertonia more quantitatively using laboratory equipment (e.g., mechatronics combined with dynamometry,

sEMG) [16, 24]. However, such momentary measurements which largely relies on manual (in clinics) or instrumented (in laboratory) examination of passive resistance to joint displacement do not capture the true presence of hypertonia during daily activities. This is because daily involvement of the paretic arm is most often marked by non-use or neglect, while performing motor tasks with the non-paretic arm or the whole body [25, 26]. As such, there often is not a good correlation between these measures and patient's ratings of abnormal tone experienced daily [11, 27, 28], and thus fail to provide useful information about the impact of hypertonia on everyday function.

Recent advances in wearable sensors, e.g., inertial measurement unit (IMU) + surface electromyography (sEMG), offer promising avenues to examine motor function of neurologically injured individuals in the real-world. As such, they have been employed in many applications in rehabilitation, e.g. to recognize motor pattern or intent for robotic prosthetics control [29-31], to detect disease symptoms or adverse events [32-34], or to provide bio-feedback during training [35]. However, there are remaining gaps in utilizing these technologies to constantly monitor an important neural signature underlying post-stroke motor impairment such as hypertonia. Most importantly, we currently lack a robust measure that can reliably quantify abnormal neural drive to paretic muscles over extended periods of time (e.g., weeks) [36, 37]. In particular, sensitivity of sEMG magnitude to noise and electrode placement makes it challenging to obtain consistent measurements across days [38-40]. For example, measurements via sEMG inherently suffers from nonstationarity of the signal, where magnitude of the signal varies with measurement condition such as electrode-skin impedance and electrode location. Further, deficits in stroke survivors to voluntarily activate their muscle raises issues in defining a reference for comparison [41-43].

In this study, we propose a novel time-based surface electromyography (sEMG) measure, Active Duration, which can overcome the limitations of the coarse clinical scales often measured in functionally irrelevant context and the challenges associated with magnitude-based sEMG measures to quantify hypertonia. We postulate that the key to robust quantification of hypertonia is to capture the "true" baseline in sEMG for each measurement session, by which we can define the length of time (i.e., duration) a muscle is active relative to this baseline using a widely accepted technique for detecting active state of a muscle from sEMG [44-46]. Such approach can be applied over a short time segment tracked in a sliding window fashion to quantify the continuous time-course of how and to what extent hypertonia is expressed, e.g., over extended period (hours) during activities of daily living. To validate the robustness of the proposed measure in real-world scenario, we first use sEMG from healthy individuals to test its robustness across parameter choices, against noise, and its reliability across measurements. Further, we demonstrate the feasibility and the utility of the proposed measure with sEMG recorded from paretic arm muscles while individuals with stroke perform various daily activities, such as, while awake, when completely relaxed, as well as during some functional activities such as ambulating in the laboratory. Results are further discussed focusing on the implications to quantifying hypertonia in paretic arm muscles during daily activities after stroke.

2. MATERIALS AND METHODS

2.1. Active duration: a time-based sEMG measure to quantify hypertonia

Our proposed time-based measure of hypertonia quantifies *Active Duration* of sEMG within a time segment, defined as the percent of time conditioned signal is above a threshold defined with signal distribution. Briefly, the method relies on robust capturing of the "true" baseline in sEMG for each measurement session using an established relaxation protocol (i.e., eliminate hyperactivity) [47, 48], from which we define the relative duration of activity over a short time segment, continuously tracked in a sliding window fashion (Fig. 1A). Specifically, four steps are involved:

1) Signal pre-processing and conditioning: Raw sEMG recorded from any muscle or channel can be pre-processed to first remove any noise known or identified to be present such as offset, powerline interference, or substantial motion artifact. Then, the signal is conditioned with Teager-Kaiser energy operator (TKEO) to improve signal-to-noise ratio [44-46]:

$$\Psi[x(n)] = x(n)^2 - x(n+1) \bullet x(n-1),$$

where x(n) denotes nth sample of the processed sEMG signal. Conditioned sEMG is then full-wave rectified.

2) Defining the segment-based minimum across all recordings (Fig. 1A, top): Processed and conditioned sEMG is examined with moving average window with a given length (*WL*) and overlap (in %) to find the minimum (μ) across all recordings for a given muscle. Here, *WL* and overlap are custom parameters that determine the temporal resolution of the final active duration measure (see section 2.2 below), just as any time-domain smoothing process would do, which also affects the computational demand (e.g., the smaller the *WL* and greater the overlap, the greater the demand).

3) Defining the threshold criteria (Fig. 1A, middle): For the segment where minimum mean (μ) was found above, standard deviation (σ) is calculated. The threshold criterion (*TC*) for defining active state of a muscle is defined as:

$$TC = \mu + N\sigma,$$

where *N* is the multiplication factor, which is a widely used method for detecting the onset in sEMG signals [44-46]. This factor *N* determines the sensitivity in detecting an active state, where ranges of numbers have been used or tested in literature [44-46], e.g., 1-3 and 3-23 for sEMG without and with TKEO conditioning, respectively. For the proposed measure active duration, *TC* determines the lower bound and the relative mapping to the signal magnitude (see section 2.2. below). While larger *TC* (e.g., $\mu+8\sigma$) is often used to detect EMG onset during voluntary movements in healthy individuals [44-46], for paretic muscles where signal-to-noise ratio (SNR) is often expected to be very low [49, 50], smaller *TC* (e.g., $\mu+3\sigma$) is recommended to more robustly capture the hyperactive muscle tone.

4) Active duration calculation (Fig. 1A, bottom): Once *TC* is defined from the previous step, this can be used to count, on segment basis (window length: *WL*), the number of datapoints that are above the threshold in percentage of time.

Results from segments in consideration can be then used to construct a continuous, time-course of active duration of sEMG, at given temporal resolution as determined by *WL* and overlap, where a different overlap interval can be used than in step 2), depending on the purpose. For example, one may choose to use greater overlap for more smooth and continuous visualization, whereas use results with no overlap to ensure statistical independence in analyzing time-series data [51]. An

142 example with WL=5 s and N=3 (i.e., $TC=\mu+3\sigma$) shows, active duration over 60 s when an
143 individual with stroke was performing various activities of daily living (see section 2.3 for detail).
144

145 ***2.2. Validating robustness and reliability of active duration measure***

146 To validate the sEMG active duration as a useful and reliable measure for daily monitoring or
147 tracking of hypertonia in home-based setting, we first used experimental data from healthy
148 individuals to systematically examine the sensitivity of sEMG active duration in detecting neural
149 drive to muscles and quantifying the degree in relation to signal magnitude (or power).
150 Specifically, we assessed the robustness of the proposed measure across parameter choices and
151 against simulated noise, and its reliability across measurements conditions.

152 2.2.1. Experimental protocol and setup

153 Total six healthy young adults (age 24-29 years; 3 females) participated. All participants gave
154 informed consent prior to the experiment. All procedures and protocols were approved by the
155 Northwestern University Institutional Review Board.

156 Participants completed two sessions, apart by a week on average (6.8±4.3 days), repeating the
157 same protocol. Each day (session), participants performed series of motor tasks mimicking
158 activities of daily living (ADL). While we ultimately seek to apply the method during any ADL,
159 for validation purposes here, we used standardized protocols that closely mimic ADL and represent
160 typical states of daily arm involvement and engaging sub-maximal level of muscle activation in a
161 controlled way.

162 • Baseline: This task represented a completely *relaxed* state, e.g., when a participant is
163 asleep/nearly asleep, where in the case of individuals with stroke, abnormal tone or
164 hypertonia is expected not to be present, providing a "true" baseline. For healthy

individuals, however, complete relaxation is readily achievable. During baseline, participants were seated on a standard chair with arm naturally supported on laps for 2.5 minutes.

- Timed Up and Go (TUG): This task represented the *ambulatory* state which involves a functional, whole-body movement. TUG is a clinical test designed to assess basic mobility in neurologically impaired individuals [52, 53]. The test is comprised of a sequence of functional maneuvers including rising from a chair (at the verbal cue 'Go'), walking 3 meters (distance indicated by a line on floor to cross), walking back, and sitting down again. In the case of individuals with hemiparetic stroke, participants are allowed to use customary walking aids (e.g., cane) used in daily living.
- Timed Dumbbell (TD): This task is designed to have participants activate different groups of muscles at a controlled level, while performing a set of isotonic dumbbell-lifting (3 different weights) with their dominant (right) arm in a standardized manner, synchronized to a digital metronome with visual and audio feedback in real time. The 3 set of weights were selected for each participant, prior to the actual experiment, at levels that will engage at least perceivable effort but not inducing any fatigue and was used consistently across the two sessions for each participant. The TD tasks targeted various Degrees of Freedom (DoF), including wrist flexion/extension (WF/WE), elbow flexion/extension (EF/EE), and shoulder abduction (ABD), each repeated 7 times (see Table 1. for detailed procedure).
- Maximum Voluntary Contraction (MVC): MVCs for wrist flexion/extension (WF/WE), elbow flexion/extension (EF/EE), and shoulder abduction (ABD) were performed to capture the maximum level of voluntary muscle activation for each session. To control for consistent posture across sessions and provide support (restraint) for engaging maximal

effort, participants were seated on the Biodex chair (Biodex Medical Systems, Inc., Shirley, New York, USA), with apertures fixed at similar range across participants while accommodating for each participant's comfort (Fig. 2B), which was kept consistent across sessions. MVC trial for each DoF lasted about 5 s each, encouraged by verbal stimuli, and were repeated 3 times, with sufficient breaks in between.

- All procedures were instructed and administered by the same licensed physical therapist to ensure consistency and repeatability.

Participants repeated the sequence of Baseline, TUG, and TD three times, with consecutively increasing weights in the TD tasks. MVC trials were completed at the end of the experiment. This order was devised to minimize the influence of potential fatigue, which was also monitored through verbal communication with the participant.

During each trial in all sessions, muscle activity was recorded at 2 kHz from the given set of target muscles across the wrist/finger, elbow, and shoulder joints (see Fig. 2 and Table 1 for detailed list and abbreviations) from the dominant (right) arm using a wireless sEMG system (Delsys Trigno™, Delsys, Natick, MA). Raw sEMG signals were manually inspected to remove any artifact or noise including powerline interference in a consistent manner using an auto-regression modeling [54] and a spectral interpolation technique [55]. In addition, tri-axial acceleration and angular rate were recorded (148.148 Hz, synchronize with sEMG signal at 2:27 ratio) with inertial measurement unit (IMU) sensors attached at the trunk (sternum), elbow (proximal to olecranon fossa), and forearm (ulnar-radial styloid) (Fig. 2). IMU signals were further low-pass filtered with zero-phase Butterworth filter (4th order) at 10 Hz cut-off frequency, which were used to detect and segment sEMG data according to each task.

Between the two sessions, two different sets of sensor elements were used (assigned in random order across participants) to incorporate potential differences between elements/channels, in addition to natural inter-day variability across measurement days (see section 2.2.4).

2.2.2. Robustness across parameter choices

Ranges of selected parameters involved in calculation of sEMG active duration (see section 2.1.) were tested. First, to examine the effect of window length (*WL*), which determines the temporal resolution of resulting active duration calculated, we tested *WL* of 0.5, 1, 2, and 5 s. This parameter can be also customized depending on the type of task being examine, e.g., slow/static vs. fast/dynamic, or computational demand such as memory and data storage size.

To emulate different sensor specification and re-sampling processes that may be potentially used, we tested sampling rates of 200 Hz, 400 Hz, 1kHz, and 2 kHz by decimating (with lowpass Chebyshev Type I infinite impulse response filter of order 8, to prevent aliasing during down-sampling) at ratio 1/10, 1/5, 1/2, and 1 of the original signal at 2 kHz, respectively.

To examine the effect of threshold criteria (*TC*) that defines the active state of a muscle, we tested the multiplication factor *N* (where $TC = \mu + N\sigma$) of 2, 3, 5, and 10.

In all cases, when the parameter of interest was systematically varied, other parameters were kept constant, which were selected as *WL*=2 s, sampling rate = 2 kHz, and *N* = 3 as default.

Finally, we were also interested in investigating the relationship between the proposed measure and the magnitude (or power) of the signal, we examined the shape of the one-to-one mapping between the sEMG active duration and root mean square (RMS) calculated with corresponding parameter (s) on segment basis. Specifically, the initial slope (at low level) and the minimum offset of this curve was used to determine the sensitivity and consistency of sEMG active duration in

233 detecting the onset state of a muscle, respectively. On the other hand, the range spanned and the
234 general shape from minimum to maximum value was used to determine the extent to which and
235 how sEMG active duration spanned the range of magnitudes (i.e., RMS).
236
237 2.2.3. Robustness against simulated noises
238 Because our method is targeted to quantify the sEMG active duration in paretic muscles, where
239 low SNR (i.e., due to paresis and deficit in voluntary activation [41-43]) and presence of abnormal
240 neural drive (e.g., involuntary, sporadic firing [56]) are expected, we emulated such conditions by
241 injecting simulated noise to the sEMG recorded from healthy individuals. In particular, we tested
242 robustness of resulting sEMG active duration against two types of noise. First, we simulated
243 overall increased background noise level in a muscle or a channel by injecting gaussian white noise
244 with varying SNR 1, 2, 5, 10, and 20 dB, generated with built-in function 'awgn.m' in Matlab
245 (Mathworks, Natick, MA), in which the power of the input (clean) signal is estimated using the
246 data from representative trials of each type concatenated for each muscle/channel.
247 In addition, to model the sporadic motor unit firing patterns with varying statistical
248 characteristics, we employed the model developed by Konstantin et al., [57], where parameters
249 were modified for muscles and the sEMG data examined in this study. Briefly, the model allows
250 for simulating synthesized sEMG signals mainly driven by the excitation profile for the motor
251 neuronal pool, while incorporating realistic motor neuron behavior, muscle fiber innervation
252 geometry, and tetanic force development [57]. Specifically, to test whether sEMG active duration
253 has the sensitivity to capture the statistical characteristics of motor unit action potential, we used
254 two types of excitation profiles (Fig. 4B, in section 3): trapezoid (15s ramp up - 15 s hold - 15s
255 ramp down) and constant with varying firing rate (at default, 1/2, and 1/5 frequency). The

synthesized EMGs were then superimposed onto the experimental sEMG data from the Baseline trials, to calculate the resulting active duration.

2.2.4. Reliability across measurements

Finally, we tested the reliability of sEMG active duration measured between two different sessions, naturally affected by inter-day variability and different set of sensor elements within an individual. Reliability was assessed with an intraclass correlation coefficient (ICC, excellent when ≥0.90, good when 0.75≤ICC<0.90, moderate when 0.50≤ICC<0.75, and poor when ICC<0.50 [58]), where 3 repetitions for each type of task in each day were considered as random effect. To this end, data from each task type was segmented to consistent length and aligned in time (using IMU signals) between the two days, which encapsulated the main task in the middle. Selected lengths for Baseline, TUG, TD, and MVC trials were 65, 35, 103, and 20 s, respectively.

2.3. Demonstrating feasibility and utility in paretic muscles

2.3.1. Experimental protocol and setup

Total three individuals with chronic hemiparetic stroke (22.0±10.5 years post stroke; age 62.7±7.5; 2 females) participated. We recruited participants who had varying levels of motor impairment, as assessed by Fugl-Meyer Assessment upper extremity portion (FMA-UE) [61], with scores apart by minimal clinically important differences [59]. All participants gave informed consent prior to the experiment. All procedures and protocols were approved by the Northwestern University Institutional Review Board.

Participants performed daily motor tasks similar to the previously described protocol (in section 2.2). However, to distinguish the baseline state when hypertonia is present or absent, we

used three different states. *Relaxed* state represents when participant is asleep/nearly asleep. Following an established protocol to maximally relax paretic muscles [60], participants sat comfortably on a supported/reclined chair in a dark quiet room with relaxing musing for 15 minutes. *Awake* state represents sedentary [61, 62], yet awake condition with paretic arm at rest. Participants were seated on a standard chair with paretic arm naturally supported. *Ambulatory* state represents involvement of the paretic arm during whole-body, functional task. Participants performed the TUG test, as described before. While MVC were collected for reference, data from these trials were not included in the analysis (see below) because individuals have difficulty in voluntarily activating the muscles, especially with more severe motor impairments [41-43]. Indeed, it was found that the magnitude of muscle activity in some participants were greater when involuntary drive was present than those observed during the MVC trials. All procedures, including the clinical test (FMA-UE) were administered by licensed physical therapist.

During the experiment, sEMG and IMU data were collected as previously described, however, using a subset of muscles for sEMG, excluding the three shoulder muscles as hypertonia is less prevalent in these proximal muscles.

2.3.2. Analysis

Our main focus was to test whether the proposed measure sEMG active duration can characterize the clinically observed differences in hypertonia expressed across different muscles and impairment levels well. Specifically, based on the well-known clinical observations and findings on prevalence of hypertonia [1, 3, 4], we hypothesized that active duration is greater in distal, than in proximal muscles, and increases with the severity of impairment level. To test this hypothesis, we used a linear mixed-effects model with active duration as dependent variable, and state (3

levels: *Relaxed*, *Awake*, and *Ambulatory*; see section 2.3.1), joint (2 levels: distal, proximal), and impairment level (i.e., FMA-UE) as fixed effects, and subject and muscle as random effects.

304 **3. RESULTS AND DISCUSSIONS**

305 ***3.1. Validation of sEMG active duration measure***

306 For brevity and clarity, here we report and discuss only the examples from a representative
307 participant and muscle TRI. Nevertheless, results were consistent across all muscles and all
308 participants. All data and codes are available upon proper request to the corresponding author.

309 3.1.1. Robustness across parameter choices

310 We found that the proposed measure was robust across parameter choices (Fig. 3). For example,
311 using larger window length had smoothing effect, as would be expected for magnitude-based
312 measure such as RMS (Fig. 3A, top left two). In relation to magnitude (Fig. 3A, right), RMS
313 normalized to 100% at MVC, sEMG active duration sensitively (i.e., sharp initial slope) and
314 robustly (i.e., consistent minimum offset) captured the active state of a muscle, lateral head of the
315 triceps (TRI) in this case, while still providing a continuum of scale over the full magnitude range
316 (i.e., range span from near-zero to 100%) in a nonlinear fashion, which asymptotically saturates at
317 ~25% RMS, however with a clearly distinguishable curve even beyond.

318 Testing across range of other parameters, such as sampling rate (Fig. 3B) and threshold criteria
319 (Fig. 3B), also demonstrated that the method may allow for parameter optimization among various
320 sensor configurations and tasks.

321 Robustness of the proposed measure sEMG active duration across ranges of various parameters
322 confer reliable quantification of hypertonia across time, at both spatial and temporal resolution far
323 exceeding the current, momentary measures in clinic- [20-22] or laboratory-based settings [16,
324 24]. Moreover, wider range of possible sEMG sensor configuration, e.g., low sampling rate, will
325 allow for the use of more power-efficient sensor systems, that are more well-suited for real-world
326 deployment, e.g., for daily use at home, outside the laboratory [32-34].

327

328 3.1.2. Robustness against simulated noise sources

329 In addition, the proposed measure was robust against typical noise sources present in paretic
330 muscles. When contaminated with gaussian white noise with varying SNR, the sEMG active
331 duration could still sensitively and robustly capture active state of a muscle (Fig. 4A, left). In the
332 case of RMS, in contrast, much of the signal was buried with low SNR (Fig. 4A, middle), which
333 would be problematic especially when applied to muscles with substantial paresis [41-43].
334 Relationship to magnitude became more linear and spanned lesser range with lower SNR, however
335 while still providing a continuum of scale that can be mapped to 0 to 100% RMS (Fig. 4A, right).

336 When we simulated noise that mimic sporadic motor neuron action potentials often observed
337 in a paretic muscle, the change in temporal profile of the sEMG active duration from Baseline
338 closely followed the excitation profile, and thus the statistical characteristics of motor unit firing
339 or recruitment (Fig. 4B, right). The magnitude-based measure RMS, on the other hand, rather
340 represented the amplitude of the injected noise (Fig. 4B, left), indicating that it will be subjected
341 to ignoring the low-level manifestation of hypertonia as small offset (or noise) in background.

342 While pathological pattern of muscle activity has been often considered as noise or practical
343 barriers in using magnitude-based sEMS measures [63, 64], our results suggest that sEMG active
344 duration may be useful for examining important neuropathological characteristics of paretic
345 muscle recruitment. Increased involuntary muscle tone (i.e., hypertonia) makes limb movement
346 difficult and is influenced by the need/demand/intention to use the paretic/nonparetic limb or the
347 whole body [65-67]. Evidence further suggests that the same neural mechanism, upregulation of
348 corticoreticulospinal system due to the lost corticofugal projections [68-70], underlies the
349 manifestation of abnormal drive to paretic muscles in various forms, resulting in the expression of

350 the flexion synergy [71-73], spasticity [74], associated reactions [75], paresis (resulting in 'learned
351 non-use' [76]) and associated functional motor deficits. Thus, provided with the exact real-world
352 context in which such deficits are experienced and manifested, the sEMG active duration can be a
353 useful measure to probe into the true impact of abnormal neural drive and resulting motor
354 impairments during activities of daily living.
355
356 3.1.3. Reliability across measurements
357 Finally, we also found that the proposed measure sEMG active duration is reliable across
358 measurements, i.e., repetitions within a day as well as across days. For example, the time trace of
359 3 repetitions of the same task in the same session for each Day 1 (Fig. 5A, left) and Day 2 (Fig.
360 5A, right) were highly repeatable, both within days as well as across days. Inter-day reliability of
361 sEMG active duration was also excellent, resulting in intra-class correlation coefficient over 0.99
362 in most muscles examined (Fig. 5B). Especially, the near-zero% value at the Baseline and near-
363 100% value at MVC were very consistent, which was the case for all muscles and individuals.
364 This result indicates that the measure (e.g., with default parameters selected in this study) provides
365 highly reliable and consistent lower and upper bounds that is comparable across muscles and
366 individuals, in stark contrast to magnitude-based sEMG measures that suffer from normalization
367 issues [41-43].
368 Furthermore, such high reliability across measurement days suggest that the sEMG active
369 duration can be a solution to the remaining challenges in using sEMG signal to obtain robust
370 measurements over extended period of time, e.g. across days or weeks [36, 37].
371

3.2. Feasibility and utility in paretic muscle: preliminary results

Our preliminary results (n=3) demonstrate that the proposed, time-based measure sEMG active duration can well characterize the clinically observed differences in hypertonia expressed across different muscles and impairment levels (Fig. 6). Using this measure, we found that hypertonia was more prevalent (i.e., active for longer duration) in distal wrist/finger muscles than proximal elbow muscles during *Awake* (t_{254}=5.45, $p<10^{-6}$) and *Ambulatory* states (t_{282}=3.54, $p<0.001$). Importantly, however, there was no difference across muscles (t_{254}=0.99, $p=0.32$) or subjects (insignificant random effect) during completely *Relaxed* state (Fig. 6A), indicating that our relaxation protocol [60] successfully quieted all muscles, and that our measure robustly quantifies the "true" baseline that is consistent/comparable across muscles and subjects, which was not the case with magnitude-based measures (e.g., RMS, normalized to MVCs). Furthermore, the amount of reduction in active duration from *Awake* to *Relaxed* state, i.e., difference between "nominal" and "true" baseline, increased as a function of impairment level (FMA-UE), more so in distal muscles (Fig. 6B; t_{254}=-3.51, $p<0.001$), indicating that individuals with more severe impairment would experience a longer period of continuous involuntary activity, especially in the distal muscles, even during an ordinary resting state while awake.

4. CONCLUSIONS

Here, we presented the work aimed at developing a time-based surface EMG measure that can be used to track stroke-induced hypertonia during activities of daily living. We validated that the sEMG active duration measure is robust across parameter choices (e.g., sampling rate, window length, threshold criteria), robust against typical noise sources present in paretic muscles (e.g., low signal-to-noise ratio, sporadic motor unit action potentials), and reliable across measurements (e.g., sensors, trials, and days), while providing a continuum of scale over the full magnitude range for each session. Furthermore, sEMG active duration could well characterize the clinically observed differences in hypertonia expressed across different muscles and impairment levels. Taken together, this novel time-based measure is well-suited for continuous and quantitative monitoring of hypertonia in the real-world, e.g., while at home, when integrated with commercially available wearable sensors that are easy-to-use (easy-to-"don and dof" and "wear") [77]. Such a monitoring system will allow for the study of practical effect of pharmacological and/or physical interventions and facilitate the investigation of daily impact of hypertonia and its underlying neural mechanisms.



Figure 1. Proposed time-based sEMG measure: Active duration. (A) Conditioned sEMG is examined with a moving average window (e.g., 5 s) to find the minimum across all recordings (top), from which a threshold of active state was defined (middle). Active duration is calculated for each segment as the percent of time amplitude was above the threshold (bottom). (B) Time trace of conditioned sEMG and calculated active duration (bottom) over 60 s from a representative participant with stroke during normal *Awake*, completely *Relaxed*, and functional *Ambulatory* states.



411

412 **Figure 2.** Sensor placement. Muscle activity (sEMG) was recorded from 3 shoulder (orange), 2

413 elbow (red), and 6 wrist/hand (purple) muscles. IMU data was recorded from two locations (trunk

414 and wrist) to monitor gross movement and to segment sEMG data based on event detection.



Figure 3. Robustness across parameter choices. (A) Resulting sEMG active duration (left) and corresponding RMS (middle) for various motor tasks, when window length is systematically varied. The relationship between active duration and RMS represented as the one-to-one mapping of active duration and RMS on segment basis (right). (B) Resulting sEMG active duration when sampling rate is systematically varied. (C) Resulting sEMG active duration when threshold criteria are systematically varied.



Figure 4. Robustness against simulated noise sources. (A) Resulting sEMG active duration (left) and corresponding RMS (middle) for various motor tasks, when background noise with varying signal-to-noise ratios (SNR) are added. The relationship between active duration and RMS (right). (B) Resulting sEMG active duration (left) and corresponding RMS (right), when simulated EMG with sporadic motor unit action potentials with varying statistical characteristics (top) are added to sEMG during baseline.



Figure 5. Reliability across measurements. (A) Active duration calculated for various tasks during three repetitions within a day, and across two sessions Day 1 (left) and Day 2 (right), that was apart by 3 days. Error bars indicate standard error (SE). (B) Inter-day reliability, as measured by intra-class correlation coefficient (ICC). (C) ICC for other four muscles for the same representative participant are displayed.



Figure 6. Preliminary results with individuals with stroke (n=3), with varying level of impairment (FMA-UE). (A) Comparison of sEMG active duration between distal wrist and proximal elbow muscles during *Awake*, *Relaxed*, and *Ambulatory* states. Each data point indicates mean±SE across 12 segments for each muscle in each state. (B) Amount of reduced time active in *Relaxed* relative to *Awake* state, as a function of impairment level (FMA-UE).

Table 1. Target muscle list for sEMG recording

Joints	Muscles	Abbrev.
Wrist	*Flexor carpi radialis*	FCR
	Flexor digitorum superficialis	FDS
	Flexor carpi ulnaris	FCU
	Extensor carpi radialis	ECR
	Extensor digitorum communis	EDC
	Extensor carpi ulnaris	ECU
Elbow	*Biceps brachii*	BIC
	Triceps brachii lateral head	TRI
Shoulder	*Anterior deltoid*	AD
	Middle deltoid	MD
	Posterior deltoid	PD

441

Table 2. Description of detailed protocols for each DoF

DoF	TD task procedure*
Wrist flexion (WF)	Upper arm on side, elbow 90°, forearm supinated with palm facing superior (up), begin from fully down (extended), 7 cycles of down-up-down at 90 BPM**
Wrist extension (WE)	Upper arm on side, elbow 90°, forearm pronated with palm facing inferior (down), begin from fully down (flexed), 7 cycles of down-up-down at 90 BPM
Elbow flexion (EF)	Upper arm on side, forearm supinated with palm facing anterior, begin from elbow fully extended (0°), 7 cycles of elbow 0°-150° (fully flexed)-0° at 70 BPM
Elbow extension (EE)	Upper arm raised on side, forearm pronated with palm facing anterior, begin from elbow fully extended (0°), 7 cycles of elbow 0°-150° (fully flexed, behind the head)-0° at 70 BPM
Shoulder abduction (Abd)	Begin from arm on side, forearm in neutral with palm facing medial, keep elbow fully extended (0°) and forearm neutral, 7 cycles of shoulder 0°-90° (prior to elevation)-0° abduction at 70 BPM

** In all cases, participants were instructed to “use only as much effort needed”.

* BPM: bit per minute.

442

Supplementary Materials: N/A.

Author Contributions: Conceptualization, M.H.S.; methodology, M.H.S. and J.D.; software, M.H.S.; validation, M.H.S. and J.P.A.D.; formal analysis, M.H.S.; investigation, M.H.S. and J.D.; resources, J.P.A.D.; data curation, M.H.S.; writing—original draft preparation, M.H.S.; writing—review and editing, M.H.S, J.D., and J.P.A.D.; visualization, M.H.S.; supervision, M.H.S. and J.P.A.D.; project administration, J.D. and J.P.A.D.; funding acquisition, J.P.A.D. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Department funds to M.H.S. and J.D., the NIH R01NS105759 to J.P.A.D. and the NIHR01HD084009 to J.P.A.D. and W.M.M

Institutional Review Board Statement: Not applicable.

Data Availability Statement: All data and codes used in this paper are available on proper request to the corresponding author: hogchul.sohn@northwestern.edu.

Acknowledgments: Any support given which is not covered by the author contribution or funding sections, e.g., administrative and technical support, or donations in kind.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

460 **REFERENCES**

461 1. Marciniak, C. "Poststroke Hypertonicity: Upper Limb Assessment and Treatment." *Top*
462 *Stroke Rehabil* 18, no. 3 (2011): 179-94.
463 2. Sheean, G., and J. R. McGuire. "Spastic Hypertonia and Movement Disorders:
464 Pathophysiology, Clinical Presentation, and Quantification." *PM R* 1, no. 9 (2009): 827-
465 33.
466 3. Li, S., D. G. Kamper, and W. Z. Rymer. "Effects of Changing Wrist Positions on Finger
467 Flexor Hypertonia in Stroke Survivors." *Muscle Nerve* 33, no. 2 (2006): 183-90.
468 4. Twitchell, T. E. "The Restoration of Motor Function Following Hemiplegia in Man." *Brain*
469 74, no. 4 (1951): 443-80.
470 5. McPherson, J. G., M. D. Ellis, C. J. Heckman, and J. P. Dewald. "Evidence for Increased
471 Activation of Persistent Inward Currents in Individuals with Chronic Hemiparetic Stroke."
472 *J Neurophysiol* 100, no. 6 (2008): 3236-43.
473 6. Broeks, J. G., G. J. Lankhorst, K. Rumping, and A. J. Prevo. "The Long-Term Outcome of
474 Arm Function after Stroke: Results of a Follow-up Study." *Disabil Rehabil* 21, no. 8
475 (1999): 357-64.
476 7. Metoki, N., Y. Sato, K. Satoh, K. Okumura, and J. Iwamoto. "Muscular Atrophy in the
477 Hemiplegic Thigh in Patients after Stroke." *Am J Phys Med Rehabil* 82, no. 11 (2003):
478 862-5.
479 8. O'Dwyer, N. J., L. Ada, and P. D. Neilson. "Spasticity and Muscle Contracture Following
480 Stroke." *Brain* 119 (Pt 5) (1996): 1737-49.
481 9. Yasar, E., F. Tok, I. Safaz, B. Balaban, B. Yilmaz, and R. Alaca. "The Efficacy of Serial
482 Casting after Botulinum Toxin Type a Injection in Improving Equinovarus Deformity in
483 Patients with Chronic Stroke." *Brain Inj* 24, no. 5 (2010): 736-9.
484 10. Bakheit, A. M., A. F. Thilmann, A. B. Ward, W. Poewe, J. Wissel, J. Muller, R. Benecke,
485 C. Collin, F. Muller, C. D. Ward, and C. Neumann. "A Randomized, Double-Blind,
486 Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three
487 Doses of Botulinum Toxin Type a (Dysport) with Placebo in Upper Limb Spasticity after
488 Stroke." *Stroke* 31, no. 10 (2000): 2402-6.
489 11. Simpson, D. M., D. N. Alexander, C. F. O'Brien, M. Tagliati, A. S. Aswad, J. M. Leon, J.
490 Gibson, J. M. Mordaunt, and E. P. Monaghan. "Botulinum Toxin Type a in the Treatment
491 of Upper Extremity Spasticity: A Randomized, Double-Blind, Placebo-Controlled Trial."
492 *Neurology* 46, no. 5 (1996): 1306-10.
493 12. Popovic, D., A. Stojanovic, A. Pjanovic, S. Radosavljevic, M. Popovic, S. Jovic, and D.
494 Vulovic. "Clinical Evaluation of the Bionic Glove." *Arch Phys Med Rehabil* 80, no. 3
495 (1999): 299-304.
496 13. Doucet, B. M., and J. A. Mettler. "Effects of a Dynamic Progressive Orthotic Intervention
497 for Chronic Hemiplegia: A Case Series." *J Hand Ther* 26, no. 2 (2013): 139-46; quiz 47.
498 14. Leung, J., L. A. Harvey, A. M. Moseley, C. Tse, J. Bryant, S. Wyndham, and S. Barry.
499 "Electrical Stimulation and Splinting Were Not Clearly More Effective Than Splinting
500 Alone for Contracture Management after Acquired Brain Injury: A Randomised Trial." *J*
501 *Physiother* 58, no. 4 (2012): 231-40.
502 15. Selles, R. W., X. Li, F. Lin, S. G. Chung, E. J. Roth, and L. Q. Zhang. "Feedback-
503 Controlled and Programmed Stretching of the Ankle Plantarflexors and Dorsiflexors in

Stroke: Effects of a 4-Week Intervention Program." *Arch Phys Med Rehabil* 86, no. 12 (2005): 2330-6.

16. Yeh, C. Y., J. J. Chen, and K. H. Tsai. "Quantifying the Effectiveness of the Sustained Muscle Stretching Treatments in Stroke Patients with Ankle Hypertonia." *J Electromyogr Kinesiol* 17, no. 4 (2007): 453-61.
17. Peraut, E., L. Taieb, C. Jourdan, F. Coroian, I. Laffont, M. Chammas, and B. Coulet. "Results and Complications of Superficialis-to-Profundus Tendon Transfer in Brain-Damaged Patients, a Series of 26 Patients." *Orthop Traumatol Surg Res* 104, no. 1 (2018): 121-26.
18. Keenan, M. A., J. I. Korchek, M. J. Botte, C. W. Smith, and D. E. Garland. "Results of Transfer of the Flexor Digitorum Superficialis Tendons to the Flexor Digitorum Profundus Tendons in Adults with Acquired Spasticity of the Hand." *J Bone Joint Surg Am* 69, no. 8 (1987): 1127-32.
19. Braun, R. M., G. T. Vise, and B. Roper. "Preliminary Experience with Superficialis-to-Profundus Tendon Transfer in the Hemiplegic Upper Extremity." *J Bone Joint Surg Am* 56, no. 3 (1974): 466-72.
20. Bohannon, R. W., and M. B. Smith. "Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity." *Phys Ther* 67, no. 2 (1987): 206-7.
21. Pandyan, A. D., G. R. Johnson, C. I. Price, R. H. Curless, M. P. Barnes, and H. Rodgers. "A Review of the Properties and Limitations of the Ashworth and Modified Ashworth Scales as Measures of Spasticity." *Clin Rehabil* 13, no. 5 (1999): 373-83.
22. Platz, T., C. Eickhof, G. Nuyens, and P. Vuadens. "Clinical Scales for the Assessment of Spasticity, Associated Phenomena, and Function: A Systematic Review of the Literature." *Disabil Rehabil* 27, no. 1-2 (2005): 7-18.
23. Ansari, N. N., S. Naghdi, S. Hasson, M. H. Azarsa, and S. Azarnia. "The Modified Tardieu Scale for the Measurement of Elbow Flexor Spasticity in Adult Patients with Hemiplegia." *Brain Inj* 22, no. 13-14 (2008): 1007-12.
24. Katz, R. T., G. P. Rovai, C. Brait, and W. Z. Rymer. "Objective Quantification of Spastic Hypertonia: Correlation with Clinical Findings." *Arch Phys Med Rehabil* 73, no. 4 (1992): 339-47.
25. Derungs, A., C. Schuster-Amft, and O. Amft. "Physical Activity Comparison between Body Sides in Hemiparetic Patients Using Wearable Motion Sensors in Free-Living and Therapy: A Case Series." *Front Bioeng Biotechnol* 6 (2018): 136.
26. Ezeugwu, V. E., and P. J. Manns. "Sleep Duration, Sedentary Behavior, Physical Activity, and Quality of Life after Inpatient Stroke Rehabilitation." *J Stroke Cerebrovasc Dis* 26, no. 9 (2017): 2004-12.
27. Burridge, J. H., D. E. Wood, H. J. Hermens, G. E. Voerman, G. R. Johnson, F. van Wijck, T. Platz, M. Gregoric, R. Hitchcock, and A. D. Pandyan. "Theoretical and Methodological Considerations in the Measurement of Spasticity." *Disabil Rehabil* 27, no. 1-2 (2005): 69-80.
28. Lechner, H. E., A. Frotzler, and P. Eser. "Relationship between Self- and Clinically Rated Spasticity in Spinal Cord Injury." *Arch Phys Med Rehabil* 87, no. 1 (2006): 15-9.
29. Atzori, M., A. Gijsberts, C. Castellini, B. Caputo, A. G. M. Hager, S. Elsig, G. Giatsidis, F. Bassetto, and H. Muller. "Electromyography Data for Non-Invasive Naturally-Controlled Robotic Hand Prostheses." *Scientific Data* 1 (2014).

30. Lu, Z., K. Y. Tong, X. Zhang, S. Li, and P. Zhou. "Myoelectric Pattern Recognition for Controlling a Robotic Hand: A Feasibility Study in Stroke." *IEEE Trans Biomed Eng* 66, no. 2 (2019): 365-72.
31. Ryser, F., T. Butzer, J. P. Held, O. Lambercy, and R. Gassert. "Fully Embedded Myoelectric Control for a Wearable Robotic Hand Orthosis." *IEEE Int Conf Rehabil Robot* 2017 (2017): 615-21.
32. Cai, S., G. Li, X. Zhang, S. Huang, H. Zheng, K. Ma, and L. Xie. "Detecting Compensatory Movements of Stroke Survivors Using Pressure Distribution Data and Machine Learning Algorithms." *J Neuroeng Rehabil* 16, no. 1 (2019): 131.
33. Jahanmiri-Nezhad, F., X. Y. Li, P. E. Barkhaus, W. Z. Rymer, and P. Zhou. "A Clinically Applicable Approach for Detecting Spontaneous Action Potential Spikes in Amyotrophic Lateral Sclerosis with a Linear Electrode Array." *Journal of Clinical Neurophysiology* 31, no. 1 (2014): 35-40.
34. Lonini, L., A. Dai, N. Shawen, T. Simuni, C. Poon, L. Shimanovich, M. Daeschler, R. Ghaffari, J. A. Rogers, and A. Jayaraman. "Wearable Sensors for Parkinson's Disease: Which Data Are Worth Collecting for Training Symptom Detection Models." *NPJ Digit Med* 1 (2018): 64.
35. Dobkin, B. H., and C. Martinez. "Wearable Sensors to Monitor, Enable Feedback, and Measure Outcomes of Activity and Practice." *Curr Neurol Neurosci Rep* 18, no. 12 (2018): 87.
36. Voerman, G. E., J. F. Fleuren, L. A. Kallenberg, J. S. Rietman, G. J. Snoek, and H. J. Hermens. "Patient Ratings of Spasticity During Daily Activities Are Only Marginally Associated with Long-Term Surface Electromyography." *J Neurol Neurosurg Psychiatry* 80, no. 2 (2009): 175-81.
37. Yamagami, M., K. M. Peters, I. Milovanovic, I. Kuang, Z. Yang, N. Lu, and K. M. Steele. "Assessment of Dry Epidermal Electrodes for Long-Term Electromyography Measurements." *Sensors (Basel)* 18, no. 4 (2018).
38. De Luca, C. J. "The Use of Surface Electromyography in Biomechanics." *Journal of Applied Biomechanics* 13, no. 2 (1997): 135-63.
39. Roy, S. H., G. De Luca, M. S. Cheng, A. Johansson, L. D. Gilmore, and C. J. De Luca. "Electro-Mechanical Stability of Surface Emg Sensors." *Medical & Biological Engineering & Computing* 45, no. 5 (2007): 447-57.
40. Beck, T. W., T. J. Housh, J. T. Cramer, M. H. Malek, M. Mielke, R. Hendrix, and J. P. Weir. "Electrode Shift and Normalization Reduce the Innervation Zone's Influence on Emg." *Medicine and Science in Sports and Exercise* 40, no. 7 (2008): 1314-22.
41. McComas, A. J., R. E. Sica, A. R. Upton, and N. Aguilera. "Functional Changes in Motoneurones of Hemiparetic Patients." *J Neurol Neurosurg Psychiatry* 36, no. 2 (1973): 183-93.
42. Sica, R. E., and O. P. Sanz. "An Electrophysiological Study of the Functional Changes in the Spinal Motoneurones of Hemiparetic Patients." *Electromyogr Clin Neurophysiol* 16, no. 5 (1976): 419-31.
43. Garmirian, LRP, JPA Dewald, and AM. Acosta. "Reduction in Voluntary Activation of Elbow and Wrist Muscles in Individuals with Chronic Hemiparetic Stroke." *bioRxiv 689364 [Preprint]* (2019).

44. Solnik, S., P. DeVita, P. Rider, B. Long, and T. Hortobagyi. "Teager-Kaiser Operator Improves the Accuracy of Emg Onset Detection Independent of Signal-to-Noise Ratio." *Acta Bioeng Biomech* 10, no. 2 (2008): 65-8.
45. Solnik, S., P. Rider, K. Steinweg, P. DeVita, and T. Hortobagyi. "Teager-Kaiser Energy Operator Signal Conditioning Improves Emg Onset Detection." *Eur J Appl Physiol* 110, no. 3 (2010): 489-98.
46. Li, X., and A. Aruin. "Muscle Activity Onset Time Detection Using Teager-Kaiser Energy Operator." *Conf Proc IEEE Eng Med Biol Soc* 2005 (2005): 7549-52.
47. Binder-Markey BI, Murray WM, Dewald JP. . "Effects of Altered Neural Input and Botulinum Toxin on Finger and Wrist Passive Properties in Chronic Hemiparetic Stroke." *medRxiv 19011312 [Preprint]* (2020).
48. Schmit, B. D., J. P. Dewald, and W. Z. Rymer. "Stretch Reflex Adaptation in Elbow Flexors During Repeated Passive Movements in Unilateral Brain-Injured Patients." *Arch Phys Med Rehabil* 81, no. 3 (2000): 269-78.
49. Dai, C., N. L. Suresh, A. K. Suresh, W. Z. Rymer, and X. Hu. "Altered Motor Unit Discharge Coherence in Paretic Muscles of Stroke Survivors." *Front Neurol* 8 (2017): 202.
50. Hameed, H. K., W. Z. Wan Hasan, S. Shafie, S. A. Ahmad, H. Jaafar, and L. N. Inche Mat. "Investigating the Performance of an Amplitude-Independent Algorithm for Detecting the Hand Muscle Activity of Stroke Survivors." *J Med Eng Technol* 44, no. 3 (2020): 139-48.
51. Ebisuzaki, W. "A Method to Estimate the Statistical Significance of a Correlation When the Data Are Serially Correlated." *Journal of Climate* 10, no. 9 (1997): 2147-53.
52. Flansbjer, U. B., A. M. Holmback, D. Downham, C. Patten, and J. Lexell. "Reliability of Gait Performance Tests in Men and Women with Hemiparesis after Stroke." *J Rehabil Med* 37, no. 2 (2005): 75-82.
53. Knorr, S., B. Brouwer, and S. J. Garland. "Validity of the Community Balance and Mobility Scale in Community-Dwelling Persons after Stroke." *Arch Phys Med Rehabil* 91, no. 6 (2010): 890-6.
54. Esquef, P. A. A., and L. W. P. Biscainho. "An Efficient Model-Based Multirate Method for Reconstruction of Audio Signals across Long Gaps." *Ieee Transactions on Audio Speech and Language Processing* 14, no. 4 (2006): 1391-400.
55. Mewett, D. T., H. Nazeran, and K. J. Reynolds. "Removing Power Line Noise from Recorded Emg." *Proceedings of the 23rd Annual International Conference of the Ieee Engineering in Medicine and Biology Society, Vols 1-4* 23 (2001): 2190-93.
56. Amma, C., T. Krings, J. Boer, and T. Schultz. "Advancing Muscle-Computer Interfaces with High-Density Electromyography." *Chi 2015: Proceedings of the 33rd Annual Chi Conference on Human Factors in Computing Systems* (2015): 929-38.
57. Konstantin, A., T. Yu, E. Le Carpentier, Y. Aoustin, and D. Farina. "Simulation of Motor Unit Action Potential Recordings from Intramuscular Multichannel Scanning Electrodes." *IEEE Trans Biomed Eng* 67, no. 7 (2020): 2005-14.
58. Koo, T. K., and M. Y. Li. "A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research." *J Chiropr Med* 15, no. 2 (2016): 155-63.
59. Hiragami, S., Y. Inoue, and K. Harada. "Minimal Clinically Important Difference for the Fugl-Meyer Assessment of the Upper Extremity in Convalescent Stroke Patients with Moderate to Severe Hemiparesis." *J Phys Ther Sci* 31, no. 11 (2019): 917-21.
60. Binder-Markey, B. I., W. M. Murray, and J. P. A. Dewald. "Passive Properties of the Wrist and Fingers Following Chronic Hemiparetic Stroke: Interlimb Comparisons in Persons

with and without a Clinical Treatment History That Includes Botulinum Neurotoxin." *Front Neurol* 12 (2021): 687624.

61. Baldwin, C., G. van Kessel, A. Phillips, and K. Johnston. "Accelerometry Shows Inpatients with Acute Medical or Surgical Conditions Spend Little Time Upright and Are Highly Sedentary: Systematic Review." *Phys Ther* 97, no. 11 (2017): 1044-65.
62. Ezeugwu, V. E., and P. J. Manns. "The Feasibility and Longitudinal Effects of a Home-Based Sedentary Behavior Change Intervention after Stroke." *Arch Phys Med Rehabil* 99, no. 12 (2018): 2540-47.
63. Chang, S. H., G. E. Francisco, P. Zhou, W. Z. Rymer, and S. Li. "Spasticity, Weakness, Force Variability, and Sustained Spontaneous Motor Unit Discharges of Resting Spastic-Paretic Biceps Brachii Muscles in Chronic Stroke." *Muscle Nerve* 48, no. 1 (2013): 85-92.
64. Liu, J., D. W. Ying, W. Z. Rymer, and P. Zhou. "Robust Muscle Activity Onset Detection Using an Unsupervised Electromyogram Learning Framework." *PLoS One* 10, no. 6 (2015).
65. Held, J. P. O., B. Klaassen, A. Eenhoorn, B. J. F. van Beijnum, J. H. Buurke, P. H. Veltink, and A. R. Luft. "Inertial Sensor Measurements of Upper-Limb Kinematics in Stroke Patients in Clinic and Home Environment." *Frontiers in Bioengineering and Biotechnology* 6 (2018).
66. Schwarz, A., M. M. C. Bhagubai, G. Wolterink, J. P. O. Held, A. R. Luft, and P. H. Veltink. "Assessment of Upper Limb Movement Impairments after Stroke Using Wearable Inertial Sensing." *Sensors (Basel)* 20, no. 17 (2020).
67. Van Meulen, F. B., B. Klaassen, J. Held, J. Reenalda, J. H. Buurke, B. J. F. Van Beijnum, A. Luft, and P. H. Veltink. "Objective Evaluation of the Quality of Movement in Daily Life after Stroke." *Frontiers in Bioengineering and Biotechnology* 3 (2016).
68. Karbasforoushan, H., J. Cohen-Adad, and J. P. A. Dewald. "Brainstem and Spinal Cord Mri Identifies Altered Sensorimotor Pathways Post-Stroke." *Nat Commun* 10, no. 1 (2019): 3524.
69. McPherson, J. G., A. Chen, M. D. Ellis, J. Yao, C. J. Heckman, and J. P. A. Dewald. "Progressive Recruitment of Contralesional Cortico-Reticulospinal Pathways Drives Motor Impairment Post Stroke." *J Physiol* 596, no. 7 (2018): 1211-25.
70. Owen, M., C. Ingo, and J. P. A. Dewald. "Upper Extremity Motor Impairments and Microstructural Changes in Bulbospinal Pathways in Chronic Hemiparetic Stroke." *Front Neurol* 8 (2017): 257.
71. Ellis, M. D., I. Schut, and J. P. A. Dewald. "Flexion Synergy Overshadows Flexor Spasticity During Reaching in Chronic Moderate to Severe Hemiparetic Stroke." *Clin Neurophysiol* 128, no. 7 (2017): 1308-14.
72. Lan, Y., J. Yao, and J. P. A. Dewald. "The Impact of Shoulder Abduction Loading on Volitional Hand Opening and Grasping in Chronic Hemiparetic Stroke." *Neurorehabil Neural Repair* 31, no. 6 (2017): 521-29.
73. Sukal, T. M., M. D. Ellis, and J. P. Dewald. "Shoulder Abduction-Induced Reductions in Reaching Work Area Following Hemiparetic Stroke: Neuroscientific Implications." *Exp Brain Res* 183, no. 2 (2007): 215-23.
74. Yang, Y., N. Sinha, R. Tian, N. Gurari, J. M. Drogos, and J. P. A. Dewald. "Quantifying Altered Neural Connectivity of the Stretch Reflex in Chronic Hemiparetic Stroke." *IEEE Trans Neural Syst Rehabil Eng* 28, no. 6 (2020): 1436-41.

75. Bhakta, B. B., J. A. Cozens, M. A. Chamberlain, and J. M. Bamford. "Quantifying Associated Reactions in the Paretic Arm in Stroke and Their Relationship to Spasticity." *Clin Rehabil* 15, no. 2 (2001): 195-206.
76. Taub, E., G. Uswatte, V. W. Mark, and D. M. Morris. "The Learned Nonuse Phenomenon: Implications for Rehabilitation." *Eura Medicophys* 42, no. 3 (2006): 241-56.
77. Feldner, H. A., C. Papazian, K. Peters, and K. M. Steele. ""It's All Sort of Cool and Interesting...But What Do I Do with It?" A Qualitative Study of Stroke Survivors' Perceptions of Surface Electromyography." *Front Neurol* 11 (2020): 1037.